Inceptive

Rounds and research, on one timeline

1. 2026-09-03
   Research

   Level 4 · Tested in the physical world

   Inceptive's fine-tuned models design CAR-T mRNAs that cleared more B cells in mice than Capstan's optimised sequence in three of five tries

   In in vivo CAR-T most effort goes into the delivery particle; this tests whether redesigning the mRNA alone, with the protein unchanged, makes a stronger drug in an animal. The models also ranked the designs before the mice were dosed, and the ranking largely held, which is what would let a company test a handful of designs instead of screening thousands.

   Timeline entry →inceptive.com ↗

2. 2023-09-07Round (unnamed)
   Round

   $100M$300M · stated by Maginative

   For: extend the capabilities of its platform

   Models and platform

   Maginative says the round tripled the valuation to over $300M; the original report appears to be the Financial Times, which was not read.

   Co-lead · NVentures (NVIDIA) ✓Co-lead · Andreessen Horowitz ✓Obvious Ventures ✓

   Reported by Maginative; pharmaphorum · maginative.com ↗

3. 2022Seed
   Round

   $20M

   For: start the company

   Not stated

   Only the year is known: pharmaphorum (Sept 2023) calls it seed funding of $20M 'last year'; a16z's Vijay Pande backed it per a later profile. No source read names the seed's investors; Andreessen Horowitz, kept here as first recorded, lists Inceptive on its own portfolio page without a round.

   Andreessen Horowitz ✓

   Reported by pharmaphorum · pharmaphorum.com ↗

Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.

See these rounds in the table →